Nxera Pharma Co., Ltd.
4565.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥89,589,826 | ¥81,364,412 | ¥81,180,552 | ¥94,172,819 |
| - Cash | ¥28,461,000 | ¥32,997,000 | ¥34,465,000 | ¥32,268,000 |
| + Debt | ¥63,140,000 | ¥64,723,000 | ¥66,264,000 | ¥67,900,000 |
| Enterprise Value | ¥124,268,826 | ¥113,090,412 | ¥112,979,552 | ¥129,804,819 |
| Revenue | ¥6,754,000 | ¥8,450,000 | ¥6,644,000 | ¥6,852,000 |
| % Growth | -20.1% | 27.2% | -3% | – |
| Gross Profit | ¥4,081,000 | ¥6,592,000 | ¥5,029,000 | ¥4,725,000 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| EBITDA | -¥1,806,000 | ¥787,000 | -¥825,000 | -¥1,574,000 |
| % Margin | -26.7% | 9.3% | -12.4% | -23% |
| Net Income | -¥1,672,000 | -¥2,377,000 | -¥760,000 | -¥1,335,000 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS Diluted | -18.48 | -26.38 | -8.45 | -14.85 |
| % Growth | 29.9% | -212.2% | 43.1% | – |
| Operating Cash Flow | -¥2,976,000 | -¥180,000 | ¥613,000 | -¥10,970,000 |
| Capital Expenditures | -¥102,000 | -¥90,000 | -¥109,000 | -¥153,000 |
| Free Cash Flow | -¥3,078,000 | -¥270,000 | ¥504,000 | -¥11,123,000 |